



(51) International Patent Classification:

A61K 31/724 (2006.01) A61P 9/10 (2006.01)
A61K 9/08 (2006.01) A61P 3/06 (2006.01)

(21) International Application Number:

PCT/US2021/048084

(22) International Filing Date:

27 August 2021 (27.08.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/071,257 27 August 2020 (27.08.2020) US

(71) Applicant: **BEREN THERAPEUTICS P.B.C.** [US/US];
9200 Sunset Blvd Ste 1010, West Hollywood, California
90069 (US).

(72) Inventors: **KERWIN, Diana**; 9200 Sunset Blvd Ste 1010,
West Hollywood, California 90069 (US). **CAMM, Jason**;
9200 Sunset Blvd Ste 1010, West Hollywood, California
90069 (US).

(74) Agent: **BARKER, Adrian**; Wilson Sonsini Goodrich &
Rosati, 650 Page Mill Road, Palo Alto, California 94304
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE WITH CYCLODEXTRINS




FIG. 3A

(57) Abstract: Disclosed herein are methods treating atherosclerosis and/or atherosclerotic cardiovascular disease (e.g., coronary artery disease (CAD), peripheral artery disease (PAD), peripheral vascular disease (PVD), stroke, chronic kidney disease (CKD) caused by atherosclerosis, end-stage kidney disease (ESKD) caused by atherosclerosis, acute kidney failure caused by atherosclerosis, atherosclerotic renovascular disease (ARVD), renal artery stenosis, aortic aneurysm, idiopathic peripheral arterial hypertension, erectile dysfunction, intermittent claudication, post-surgical or iatrogenic arterial disease) by administering a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin to the subject. In some cases, the therapeutically effective amount is an amount sufficient to increase a circulating and/or systemic level of one or more sterol or oxysterol in the subject compared to a baseline, an amount effective to increase a level of ABCA1 and/or ABCG1 in the subject compared to a baseline, an amount effective to increase a level of plasma

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*